The Patent Finder

Numab Therapeutics AG

16 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
May 2034
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Jul 23, 2027
    The maintenance fee for Hetero-dimeric multi-specific antibody format (US 11,879,005) comes due Jul 23, 2027. Unpaid by Jan 24, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 1 of the patents on this record was granted since Aug 17, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,077,312CD3 and IL-23 receptor binding bispecific constructs and their use in the treatment of various diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,174,102Novel Antibody Frameworks
In force
 · High confidence
In forceHigh confidence
US 11,427,628Novel Antibody Frameworks
In force
 · High confidence
In forceHigh confidence
US 11,879,005Hetero-dimeric multi-specific antibody format
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,236,150Hetero-dimeric multi-specific antibody format
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,774,140Anti-TNFα-antibodies and functional fragments thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,365,240Novel Anti-Hsa Antibodies
In force
 · High confidence
In forceHigh confidence
US 11,578,133Antibodies Targeting CD137 and Methods of Use Thereof
In force
 · Medium confidence
In forceMedium confidence
US 12,077,588Antibodies targeting PDL1 and methods of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,319,371Novel ANTI-CD3 Antibodies
In force
 · High confidence
In forceHigh confidence
10 of 16 patents shown.
Pro members see all 16.
Pro members: see all 16 patents

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

7 pending · 1 abandoned · 5 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited